MedTrace Logo

Phase III Study to Evaluate the Efficacy and Safety of AGSAVI in Patients With Essential Hypertension

NCT04686643 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 306

Last updated 2020-12-29

No results posted yet for this study

Summary

A phase 3 study to evaluate efficacy and safety of AGSAVI

Conditions

Interventions

DRUG

AGSAVI

S-amlodipine, Valsartan, Indapamide

DRUG

AGLS

S-amlodipine, Valsartan

Sponsors & Collaborators

  • Ahn-Gook Pharmaceuticals Co.,Ltd

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-02-01
Primary Completion
2022-02-01
Completion
2022-05-01

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04686643 on ClinicalTrials.gov